Masimo Receives FDA Clearance for Noninvasive Hemoglobin Technology

Masimo has been granted FDA approval for its breakthrough noninvasive and continuous total hemoglobin monitoring technology (SpHb).

The technology should make hemoglobin measurement more convenient and available to clinicians in hospital and outpatient settings, according to the company. It is designed to improve patient safety and decrease costs.

Noninvasive total hemoglobin will be offered as part of the upgradable Masimo Rainbow SET technology platform. The company said it expects the technology will be available to select customers by the third quarter of this year.